{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:26:40Z","timestamp":1783013200692,"version":"3.54.6"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trastuzumab-based chemotherapy is the standard first-line treatment for patients with human epidermal growth factor receptor 2 (HER2)\u2013positive advanced or metastatic gastric cancer (GC). However, evidence on real-world outcomes according to the chemotherapy backbone remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 2399 patients with GC treated with trastuzumab-based chemotherapy were analyzed, of whom 486 patients were treated with trastuzumab\/5-fluorouracil\/cisplatin (HFP) and 1913 patients were treated with trastuzumab\/capecitabine\/cisplatin (HXP). Time to subsequent treatment (TST) and overall survival (OS) were analyzed according to the type of chemotherapy backbone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With a median follow-up of 10.5\u2009months, the median TST was 6.08\u2009months (95% confidence interval [CI], 5.65\u20136.60) in the HFP group and 8.02\u2009months (95% CI, 7.72-8.57) in the HXP group (P\u2009&amp;lt;\u2009.0001). The median OS was 9.89\u2009months (95% CI, 8.94-10.87) for the HFP group and 13.27\u2009months (95% CI, 12.75-14.00) for the HXP group (P\u2009&amp;lt;\u2009.0001). Specifically, HXP followed by trastuzumab and capecitabine maintenance (HXP-HX) demonstrated the best outcomes with median TST of 13.44\u2009months (95% CI, 12.52-15.61) and median OS of 22.18\u2009months (95% CI, 20.83-24.44) compared with HXP followed by trastuzumab maintenance (HXP-H) and HXP alone (both P\u2009&amp;lt;\u2009.0001), which were also significant in multivariable analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Trastuzumab\/capecitabine\/cisplatin followed by trastuzumab\/capecitabine maintenance showed the best survival outcomes for patients with locally advanced unresectable or metastatic HER2-positive GC based on real-world big data analysis of the Trastuzumab for Gastric Cancer regimen, suggesting that HXP-HX is recommended over HXP-H. In the current immunotherapy era for HER2-positive GC, the potential role of capecitabine maintenance as part of combination strategies should be interpreted cautiously and warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag196","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:44:08Z","timestamp":1778845448000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment outcomes of trastuzumab-based chemotherapy in patients with HER2-positive gastric cancer: a nationwide retrospective cohort study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1378","authenticated-orcid":false,"given":"Tae-Hwan","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Ajou University School of Medicine , Suwon 16499,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Won","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Ajou University School of Medicine , Suwon 16499,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Sun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Ajou University School of Medicine , Suwon 16499,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Yun","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Ajou University School of Medicine , Suwon 16499,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-204X","authenticated-orcid":false,"given":"Jin-Hyuk","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Ajou University School of Medicine , Suwon 16499,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-9686","authenticated-orcid":false,"given":"Hyun Woo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Ajou University School of Medicine , Suwon 16499,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026070213065322300_oyag196-B1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4143\/crt.2024.252","article-title":"Prediction of cancer incidence and mortality in Korea, 2024","volume":"56","author":"Jung","year":"2024","journal-title":"Cancer Res Treat"},{"key":"2026070213065322300_oyag196-B2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026070213065322300_oyag196-B3","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026070213065322300_oyag196-B4","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026070213065322300_oyag196-B5","doi-asserted-by":"crossref","first-page":"e74389","DOI":"10.2196\/74389","article-title":"Burden and future trends of gastric cancer in 5 east Asian countries from 1990 to 2036: epidemiological study analysis using the global burden of diseases study 2021","volume":"11","author":"Guo","year":"2025","journal-title":"JMIR Cancer"},{"key":"2026070213065322300_oyag196-B6","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cancers16071336","article-title":"HER2-positive gastric cancer and antibody treatment: state of the art and future developments","volume":"16","author":"Scheck","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026070213065322300_oyag196-B7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"2026070213065322300_oyag196-B8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"2026070213065322300_oyag196-B9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"2026070213065322300_oyag196-B10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejca.2014.12.015","article-title":"Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer","volume":"51","author":"Ryu","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026070213065322300_oyag196-B11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00280-019-03820-7","article-title":"Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial","volume":"83","author":"Rivera","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026070213065322300_oyag196-B12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12029-021-00594-1","article-title":"Trastuzumab\u2009\u00b1\u2009capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: retrospective observational real-life data of Turkish oncology group","volume":"53","author":"G\u00fcrb\u00fcz","year":"2022","journal-title":"J Gastrointest Cancer"},{"key":"2026070213065322300_oyag196-B13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00432-019-03060-5","article-title":"A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy","volume":"146","author":"Li","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026070213065322300_oyag196-B14","volume-title":"International Statistical Classification of Diseases and Related Health Problems: Alphabetical Index","author":"Organization WH","year":"2004"},{"key":"2026070213065322300_oyag196-B15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1186\/s12885-022-10006-7","article-title":"Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Cancer"},{"key":"2026070213065322300_oyag196-B16","doi-asserted-by":"crossref","first-page":"e2118457","DOI":"10.1001\/jamanetworkopen.2021.18457","article-title":"Global incidence and mortality of gastric cancer, 1980-2018","volume":"4","author":"Wong","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026070213065322300_oyag196-B17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070213065322300_oyag196-B18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.gastro.2021.03.023","article-title":"Global patterns and trends in gastric cancer incidence rates (1988-2012) and predictions to 2030","volume":"161","author":"Lin","year":"2021","journal-title":"Gastroenterology"},{"key":"2026070213065322300_oyag196-B19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"2026070213065322300_oyag196-B20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"key":"2026070213065322300_oyag196-B21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"key":"2026070213065322300_oyag196-B22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12885-021-09118-3","article-title":"Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study","volume":"22","author":"Sano","year":"2022","journal-title":"BMC Cancer"},{"key":"2026070213065322300_oyag196-B23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-020-07176-7","article-title":"Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses","volume":"20","author":"Matsumoto","year":"2020","journal-title":"BMC Cancer"},{"key":"2026070213065322300_oyag196-B24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070213065322300_oyag196-B25","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/annonc\/mdf323","article-title":"Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer","volume":"13","author":"Kim","year":"2002","journal-title":"Ann Oncol"},{"key":"2026070213065322300_oyag196-B26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12885-021-08058-2","article-title":"Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"2026070213065322300_oyag196-B27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00280-015-2881-x","article-title":"Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study","volume":"76","author":"Kim","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026070213065322300_oyag196-B28","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"2026070213065322300_oyag196-B29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026070213065322300_oyag196-B30","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026070213065322300_oyag196-B31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"2026070213065322300_oyag196-B32","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"2026070213065322300_oyag196-B33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070213065322300_oyag196-B34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.23876\/j.krcp.22.077","article-title":"Validation of operational definitions of mortality in a nationwide hemodialysis population using the Health Insurance Review and Assessment Service databases of Korea","volume":"43","author":"Lee","year":"2024","journal-title":"Kidney Res Clin Pract"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag196\/68345919\/oyag196.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag196\/68345919\/oyag196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag196\/68345919\/oyag196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:09:43Z","timestamp":1783012183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag196\/8688185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag196","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,20]]},"article-number":"oyag196"}}